Cyclerion Therapeutics, Inc.

Ironwood Pharmaceuticals, Inc.

Abbott Laboratories Corporation

Abbvie Inc.

Enanta Pharmaceuticals, Inc.

Tisento Therapeutics Inc.

Rajesh R Iyengar

Thomas Wai-Ho Lee

Paul A Renhowe

Takashi Nakai

Glen Robert Rennie

Joon Jung

Ara Mermerian

Nicholas Robert Perl

G-Yoon Jamie Im

Timothy Claude Barden

Joel D Moore

Karthik Iyer

James Edward Sheppeck

Mark G Currie

Philip R Kym

Xiang Y Yu

Lei Jia

Colleen Hudson

Kimberly Kafadar Long

George Todd Milne

Andrew J Souers

Kim Tang

Angelika Fretzen

James Jia

Peter Germano

Zhili Xin

Todd M Hansen

Andrew S Judd

Mathew M Mulhern

Gang Zhao

Charles Kim

Ju Gao

Zhonghua Pei

Bo Liu

Vince S Yeh

Jason Matthew Rohde

Yat Sun Or

Hing L Sham

Gang Liu

Michael A Patane

Ly Tam Phan

Anil Vasudevan

Richard F Clark

Matthew J LaMarche

Martin P Maguire

Su-Jen Lai

Christopher Blackburn

Courtney A Cullis

Dariusz Wodka

Daniel P Zimmer

Yanchun Wang

Robert F Keyes

John K Lynch

Hongyu Zhao

Jennifer C Freeman

Tianyuan Zhang

James A Brown

Nicholas Perl

Mei Liu

Mary Katherin Verzal

Maria D Ribadeneira

Matthew J Lamarche

Yugui Gu

Ernst U Frevert

Barbara L Cool

Jennifer L Che

James Brown

Paul Allen Renhowe

Paul Allan Renhowe

Mary Katherine Verzal

Mark Currie

Bo X Liu

Todd Matthew Hansen

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula I:

sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I:

SGC stimulators

The present disclosure relates to the use of stimulators of soluble guanylate cyclase (sGC), pharmaceutically acceptable salts thereof and pharmaceutical formulations or dosage forms comprising them, alone or in combination with one or more additional agents, for the treatment of various CNS diseases, wherein an increase in sGC stimulation, or an increase in the concentration of nitric oxide (NO), or cyclic guanosine 3',5&#x2032;-monophosphate (cGMP) or both, or an upregulation of the NO pathway is desirable.

Treatment of CNS diseases with sGC stimulators

Compounds of Formulae I' and I are described, which are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds are also useful for treating, preventing or managing various disorders that are herein disclosed. 

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) and/or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP) might be desirable. Various compounds are disclosed, including those of Formula (I). 

The present patent application discloses the compounds according to Formula (I) shown below, or pharmaceutically acceptable salts thereof wherein J, n, R, R, R, R, R, m and X as defined herein. 

Phosphorus prodrugs of pyrazolo-substituted pyrimidine sGC stimulators

The present disclosure relates to stimulators of soluble guanylate cyclase (sGC), pharmaceutical formulations comprising them and their uses thereof, alone or in combination with one or more additional agents, for treating various diseases, wherein an increase in the concentration of nitric oxide (NO) or an increase in the concentration of cyclic Guanosine Monophosphate (cGMP), or both, or an upregulation of the NO pathway is desirable. The compounds are of Formula I: 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, J, n, J, J, X, Z, Z, R, R, Y, R, o and W are as defined herein.

Compounds of Formula I are described. They are useful as stimulators of sGC, particularly NO-independent, heme-dependent stimulators. These compounds may be useful for treating, preventing or managing various disorders that are herein disclosed. 

The present patent application discloses at least the compounds according to Formula I' shown below, or pharmaceutically acceptable salts thereof, wherein ring D, ring A, ring E, ring F, J, n, J, J, o, R, R, W, J, r, J, s, Z, Zand Zare as defined herein.

Growing community of inventors

West Newton, MA, United States of America

Rajesh R Iyengar